Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric fumors, and brain metastases)

Carlo Fallai, Patrizia Olmi

Research output: Contribution to journalArticle

Abstract

The authors review the main contributions of the international literature concerning the role of hyperfractionation (HF), accelerated fractionation (AF), and accelerated hyperfractionation (AHF) of the dose in radiation therapy (RT) of central nervous system tumors. Basic rationales, clinical results, acute/late toxicity, and current prospectives are summarized in three sections focusing on malignant gliomas, pediatric brainstem tumors, and brain metastases. In supratentorial malignant gliomas the superiority of AHF (0.89 Gy x 3 fractions/day; total dose 61.4 Gy) over conventional fractionation ((CF) total dose 58 Gy) was demonstrated by a randomized trial. However, the gain in median survival time was less than 6 months. No other randomized trials support the preferential choice of non-CF schedules outside clinical trials. Ongoing trials are exploring the role of AHF in combination with chemotherapy, hypoxic cell and radiosensitizing agents. As for pediatric brainstem tumors, there are no data to support the routine use of HF that should be preferably used in an investigative setting. As late sequelae have been reported in the few long-term survivors, patients should be carefully selected. Regarding brain metastases AF RT and AHF RT, with their faster treatment course, may represent a convenient alternative to CF RT for the palliation of brain metastases. In carefully selected patients with solitary brain metastases non-CF RT may be part of aggressive treatment approaches.

Original languageEnglish
Pages (from-to)235-246
Number of pages12
JournalRadiotherapy and Oncology
Volume43
Issue number3
DOIs
Publication statusPublished - Jun 1997

Fingerprint

Central Nervous System Neoplasms
Glioma
Radiotherapy
Pediatrics
Neoplasm Metastasis
Brain Stem Neoplasms
Brain
Dose Fractionation
Radiation-Sensitizing Agents
Combination Drug Therapy
Survivors
Appointments and Schedules
Clinical Trials
Survival
Therapeutics

Keywords

  • Accelerated
  • Brain metastases
  • Central nervous system
  • Gliomas
  • Hyperfractionated
  • Pediatric
  • Radiation therapy
  • Tumors

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

@article{a3ce0e9388d54e3a9eabd713262c8d6f,
title = "Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric fumors, and brain metastases)",
abstract = "The authors review the main contributions of the international literature concerning the role of hyperfractionation (HF), accelerated fractionation (AF), and accelerated hyperfractionation (AHF) of the dose in radiation therapy (RT) of central nervous system tumors. Basic rationales, clinical results, acute/late toxicity, and current prospectives are summarized in three sections focusing on malignant gliomas, pediatric brainstem tumors, and brain metastases. In supratentorial malignant gliomas the superiority of AHF (0.89 Gy x 3 fractions/day; total dose 61.4 Gy) over conventional fractionation ((CF) total dose 58 Gy) was demonstrated by a randomized trial. However, the gain in median survival time was less than 6 months. No other randomized trials support the preferential choice of non-CF schedules outside clinical trials. Ongoing trials are exploring the role of AHF in combination with chemotherapy, hypoxic cell and radiosensitizing agents. As for pediatric brainstem tumors, there are no data to support the routine use of HF that should be preferably used in an investigative setting. As late sequelae have been reported in the few long-term survivors, patients should be carefully selected. Regarding brain metastases AF RT and AHF RT, with their faster treatment course, may represent a convenient alternative to CF RT for the palliation of brain metastases. In carefully selected patients with solitary brain metastases non-CF RT may be part of aggressive treatment approaches.",
keywords = "Accelerated, Brain metastases, Central nervous system, Gliomas, Hyperfractionated, Pediatric, Radiation therapy, Tumors",
author = "Carlo Fallai and Patrizia Olmi",
year = "1997",
month = "6",
doi = "10.1016/S0167-8140(96)01897-X",
language = "English",
volume = "43",
pages = "235--246",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric fumors, and brain metastases)

AU - Fallai, Carlo

AU - Olmi, Patrizia

PY - 1997/6

Y1 - 1997/6

N2 - The authors review the main contributions of the international literature concerning the role of hyperfractionation (HF), accelerated fractionation (AF), and accelerated hyperfractionation (AHF) of the dose in radiation therapy (RT) of central nervous system tumors. Basic rationales, clinical results, acute/late toxicity, and current prospectives are summarized in three sections focusing on malignant gliomas, pediatric brainstem tumors, and brain metastases. In supratentorial malignant gliomas the superiority of AHF (0.89 Gy x 3 fractions/day; total dose 61.4 Gy) over conventional fractionation ((CF) total dose 58 Gy) was demonstrated by a randomized trial. However, the gain in median survival time was less than 6 months. No other randomized trials support the preferential choice of non-CF schedules outside clinical trials. Ongoing trials are exploring the role of AHF in combination with chemotherapy, hypoxic cell and radiosensitizing agents. As for pediatric brainstem tumors, there are no data to support the routine use of HF that should be preferably used in an investigative setting. As late sequelae have been reported in the few long-term survivors, patients should be carefully selected. Regarding brain metastases AF RT and AHF RT, with their faster treatment course, may represent a convenient alternative to CF RT for the palliation of brain metastases. In carefully selected patients with solitary brain metastases non-CF RT may be part of aggressive treatment approaches.

AB - The authors review the main contributions of the international literature concerning the role of hyperfractionation (HF), accelerated fractionation (AF), and accelerated hyperfractionation (AHF) of the dose in radiation therapy (RT) of central nervous system tumors. Basic rationales, clinical results, acute/late toxicity, and current prospectives are summarized in three sections focusing on malignant gliomas, pediatric brainstem tumors, and brain metastases. In supratentorial malignant gliomas the superiority of AHF (0.89 Gy x 3 fractions/day; total dose 61.4 Gy) over conventional fractionation ((CF) total dose 58 Gy) was demonstrated by a randomized trial. However, the gain in median survival time was less than 6 months. No other randomized trials support the preferential choice of non-CF schedules outside clinical trials. Ongoing trials are exploring the role of AHF in combination with chemotherapy, hypoxic cell and radiosensitizing agents. As for pediatric brainstem tumors, there are no data to support the routine use of HF that should be preferably used in an investigative setting. As late sequelae have been reported in the few long-term survivors, patients should be carefully selected. Regarding brain metastases AF RT and AHF RT, with their faster treatment course, may represent a convenient alternative to CF RT for the palliation of brain metastases. In carefully selected patients with solitary brain metastases non-CF RT may be part of aggressive treatment approaches.

KW - Accelerated

KW - Brain metastases

KW - Central nervous system

KW - Gliomas

KW - Hyperfractionated

KW - Pediatric

KW - Radiation therapy

KW - Tumors

UR - http://www.scopus.com/inward/record.url?scp=0030949096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030949096&partnerID=8YFLogxK

U2 - 10.1016/S0167-8140(96)01897-X

DO - 10.1016/S0167-8140(96)01897-X

M3 - Article

C2 - 9215782

AN - SCOPUS:0030949096

VL - 43

SP - 235

EP - 246

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -